{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:08Z","timestamp":1756282208239,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Dysphagia, a well-recognised adverse effect in many different antipsychotics, is not a formally acknowledged side effect in zuclopenthixol. This case report describes a patient with known bipolar affective disorder who had been recently stabilised on zuclopenthixol decanoate and presented with sudden onset severe oropharyngeal dysphagia. Symptoms spontaneously resolved with the discontinuation of the medication, and this report explores the suggested underlying mechanisms from literature.<\/jats:p>","DOI":"10.1136\/bcr-2025-265171","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:55:20Z","timestamp":1747065320000},"page":"e265171","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Zuclopenthixol decanoate induced dysphagia"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6717-9400","authenticated-orcid":false,"given":"Olivia","family":"Dupere","sequence":"first","affiliation":[{"name":"Mersey and West Lancashire Teaching Hospitals NHS Trust, Southport, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9251-7990","authenticated-orcid":false,"given":"Haeun","family":"Ji","sequence":"additional","affiliation":[{"name":"Wirral University Teaching Hospital NHS Foundation Trust, Upton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Williams","sequence":"additional","affiliation":[{"name":"Mersey Care NHS Foundation Trust, Southport, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2025082700331184000_18.5.e265171.1","unstructured":"National Center for Biotechnology Information . PubChem compound summary for cid 5311507, zuclopenthixol. National Library of Medicine (US). 2024 Available: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Zuclopenthixol"},{"key":"2025082700331184000_18.5.e265171.2","doi-asserted-by":"crossref","unstructured":"Taylor DM , Barnes TRE . The maudsley prescribing guidelines in psychiatry. John Wiley & Sons, Ltd, 2021.","DOI":"10.1002\/9781119870203"},{"key":"2025082700331184000_18.5.e265171.3","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","volume":"2012","author":"Jayakody","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082700331184000_18.5.e265171.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-006-9032-9"},{"key":"2025082700331184000_18.5.e265171.5","doi-asserted-by":"publisher","DOI":"10.1007\/PL00009533"},{"key":"2025082700331184000_18.5.e265171.6","doi-asserted-by":"publisher","DOI":"10.1177\/089198879600900305"},{"key":"2025082700331184000_18.5.e265171.7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.9740\/mhc.2017.03.056","article-title":"Dysphagia with second-generation antipsychotics: A case report and review of the literature","volume":"7","author":"Crouse","year":"2017","journal-title":"Ment Health Clin"},{"key":"2025082700331184000_18.5.e265171.8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/ppc.12062","article-title":"Biological perspectives: Choking and antipsychotics: is this a significant concern?","volume":"50","author":"Visser","year":"2014","journal-title":"Perspect Psychiatr Care"},{"key":"2025082700331184000_18.5.e265171.9","unstructured":"Medicines and Healthcare products Regulatory Agency . Interactive drug analysis profile: zuclopenthixol. 2024 Available: https:\/\/info.mhra.gov.uk\/drug-analysis-profiles\/dap.html"},{"key":"2025082700331184000_18.5.e265171.10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1192\/bjp.164.6.849b","article-title":"Dysphagia in the neuroleptic malignant syndrome","volume":"164","author":"Shamash","year":"1994","journal-title":"Br J Psychiatry"},{"key":"2025082700331184000_18.5.e265171.11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.30773\/pi.2017.06.05","article-title":"A Neuroleptic Malignant Syndrome Without Rigidity","volume":"15","author":"\u00d6zdemir","year":"2018","journal-title":"Psychiatry Investig"},{"key":"2025082700331184000_18.5.e265171.12","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118795333"},{"key":"2025082700331184000_18.5.e265171.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-7-201004060-00006"},{"key":"2025082700331184000_18.5.e265171.14","doi-asserted-by":"crossref","unstructured":"K\u00fc\u00e7\u00fck \u00d6 , Yaylac\u0131 F , Erkuran H\u00d6 . Oropharyngeal dysphagia induced by zuclopenthixol acetate. Case Reports Presentations, Psychiatry and Clinical Psychopharmacology 2018;28. doi:10.1080\/24750573.2018.1467600","DOI":"10.1080\/24750573.2018.1467600"},{"key":"2025082700331184000_18.5.e265171.15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/NDT.S2367","article-title":"Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics","volume":"4","author":"Nagamine","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025082700331184000_18.5.e265171.16","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(90)90001-L"},{"key":"2025082700331184000_18.5.e265171.17","first-page":"61","article-title":"Antipsychotic-Induced Laryngeal Dystonia","volume":"52","author":"O\u2019Neill","year":"2022","journal-title":"Psychopharmacol Bull"},{"key":"2025082700331184000_18.5.e265171.18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gastrohep.2018.09.010","article-title":"Systematic review of case reports of oropharyngeal dysphagia following the use of antipsychotics","volume":"42","author":"Miarons","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"2025082700331184000_18.5.e265171.19","first-page":"595","article-title":"Pharmacological considerations in antipsychotic drug selection for prevention of drug-induced dysphagia","volume":"75","author":"Koshiishi","year":"2020","journal-title":"Pharmazie"},{"key":"2025082700331184000_18.5.e265171.20","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:33:20Z","timestamp":1756280000000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,12]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bcr-2025-265171"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265171","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}